ArticleNature communications2026

Intranasal administration of broad-spectrum macrocyclic peptide inhibitor protects against SARS-CoV-2 Omicron variants.

Min Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.